ProCE Banner Activity

CARES: 96-Wk Efficacy and Safety of LA CAB + RPV in Sub-Saharan Africa

Conference Coverage
Slideset

Extended follow-up (96 weeks) analysis of the CARES trial showed that switching to long-acting cabotegravir plus rilpivirine continued to result in high and noninferior virologic suppression vs continuing oral ART in a sub-Saharan African population managed under a public health approach.

Released: March 13, 2025

Expiration: September 12, 2025

Share

Provided by

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare